Be part of building a better future for cancer care.
We're building technologies and services to re-imagine cancer care - from where we treat cancer to how we support people with cancer.
Our clinical research program aims to produce high quality data in support of quality-of-life and cost of care management in cancer care. If you're a patient, provider, or researcher, and you want to participate in the future of cancer care - let us know.
Active Clinical Research Opportunities
We are actively enrolling clinical sites for participation in our clinical research program across the United States.

LOTUS-ONE: Financial Toxicity Research
LOTUS-ONE is a series of single-center feasibility studies aiming to establish the financial benefit of home infusion services.
IMPACT: Preventing Peripheral Neuropathy
IMPACT is a multinational randomized study aiming to demonstrate the efficacy of the Lilac device in reducing CIPN occurence.
HORIZON: Device-Led Home Infusion
HORIZON is a feasibility study of patient-led home infusion of select immunotherapy agents using the Lotus Infusion Set.
Our clinical research focus areas
Luminate's mission is to make cancer care more human - because the system isn't working for the people in it. Our clinical research division focuses on building the evidence for new technologies and services that can make cancer care better.
We develop and pilot new technologies alongside partnering with industry, academia, physicians and patient advocates to identify and answer important research questions for the future of cancer care.
Interested in a research collaboration? Let us know! We want to hear about new ideas for how we can make cancer care easier, more affordable, or less burdensome for patients.
Meet our Clinical Research Leadership
Our team is based across both the US and Ireland.
We’re partnering with organizations to bring more efficient, outcome-focused cancer care into the real world.
If you’re interested in piloting, modelling cost impact, or discussing integration then we’d love to hear from you.






















